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 Introduction 
 Human papillomavirus type 16 (HPV-16) infections in 
humans are associated with most cervical cancers, and 
expression of the early oncogenic proteins E6 and E7 is 
required to maintain the transformed state of the tumor cell. 
E6 and E7 proteins are co-expressed in most HPV-containing 
cervical cancers. Th ese oncoproteins are believed to sustain 
the malignant state by disrupting the cell cycle regulatory 
proteins p53 and Retinoblastoma protein, pRb. Specifi cally, 
HPV-16 E7 binds and destabilizes pRb, allowing unsched-
uled entry into the S-phase of the cell cycle (zur Hausen 
1996). Th erefore, E7 is an attractive target not only for devel-
opment of cancer vaccine to prevent cervical tumors, but it 
is also a good model for exploration of immunotherapeutic 
approaches to stimulate immune responses against existing 
HPV-16-associated malignancies (Bosch et  al. 1995, Melief 
et  al. 2000). Specifi c immunity against HPV-16-transformed 
tumors in murine models has been achieved by a number 
of vaccine strategies such as gene therapy with E7 (Duggan 
et  al. 1998, Chen et  al. 2000). 
 Gene therapy, the transfer of genes for therapeutic 
benefi t, off ers the potential for permanent cure of cancers. 
Th e success in gene therapy depends on an effi  cient strategy 
for the delivery of nucleic acid into the target cells. Both 
viral and nonviral vectors have been used in clinical trials 
to treat several forms of cancers (Somia and Verma 2000). 
Although, nonviral vectors are less effi  cient in successfully 
delivering the genes into target cell, they enjoy the advan-
tage of higher biodegradability and lower toxicity. Nonviral 
carriers are less immunogenic and more convenient (Pouton 
and Seymour 2001, Ferber 2001). 
 Positively charged polymers (referred to as polycations) 
are promising carriers among nonviral vectors. Many cat-
ionic polymers, such as cationic polysaccharides, cationic 
liposomes, dendrimers, polylysine, polyethyleneimine, and 
poly (a-(4-aminobutyl)-L-glycolic acid), have been studied 
for gene delivery. Amongst them, chitosan (CS) is a particu-
larly attractive cationic vector derived from polysaccharides. 
Polysaccharides are the most abundant polymers in nature 
and CS exhibits desirable characteristics such as biocompat-
ibility and biodegradability that is essential for gene delivery 
(Bozkir and Saka 2004). CS is also nonimmunogenic and 
nontoxic. Th e positive charge of CS allows for easily prepared 
NPs through electrostatic interaction between negatively 
charged pDNA and positively charged CS. CS has extensively 
been studied for drug delivery, therefore its advantageous 
characteristics for delivery both  in vivo and in vivo have 
been broadly investigated. 
 CS is a linear cationic polysaccharide composed of  β 1 4 
linked glucosamine and partially containing N-acetylglu-
cosamine as shown in Figure 1 (Onishi and Machida 1999, 
Wu et  al. 2005). 
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 Abstract 
 Chitosan nanoparticles (CS NPs) were prepared as a carrier 
for Human papillomavirus type 16 HPV-16) E7 gene and their 
gene transfection ability were evaluated  in vitro . The plasmid 
expressing green fl uorescent protein (pEGFP) was used as a 
reporter gene. Gel electrophoresis demonstrated full binding 
of CS NPs with the pDNA. The transfection of CS-pEGFP NPs was 
effi  cient in CHO cells and the expression of green fl uorescent 
proteins was well observed. The expression of E7 proteins was 
confi rmed under SDS-PAGE and western blot analysis. As a 
conclusion CS NPs may serve as an eff ective nonviral carrier for 
delivery of nucleotides into eukaryotic cells. 
 Keywords:  chitosan NPs ,  CHO cell line ,  gene delivery ,  HPV-16 E7 
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 In this study chitosan nanoparticles (CS NPs) were 
acquired by the process of ionotropic gelation based on the 
interaction between the negative groups of the pentasodium 
tripolyphosphate (TPP) and the positively charged amino 
groups of CS (Vila et  al. 2004). Th e particles are hydrophilic, 
biocompatible, and biodegradable. Th ese NPs are ideal for 
therapeutic targeting (Agnihotri et  al. 2004). Furthermore, 
they bear a high density of positive charges along its poly-
meric chain, which is necessary to condense the negatively 
charged DNA into compact structures, giving them protec-
tion during cellular traffi  cking and promoting its uptake to 
cells (Rudzinski and Aminabhavib 2010). 
 In this study, a CS vector with improved transfection effi  -
ciency  in vitro cell culture system as well as  in vivo mouse 
model system was prepared. Th e transfection effi  ciency was 
investigated by examination of EGFP expression in CHO 
cells treated with CS – pEGFP NPs through fl uorescence 
microscopy. Cell viability was also evaluated in CHO cells. 
Based on our fi ndings, CS – HPV-16 E7 NPs may be a promis-
ing carrier for gene therapy in cancer. 
 Materials and methods 
 Plasmid propagation and extraction 
 Bacterial strain  Escherichia coli DH5 α (Pasteur Institute 
of Iran) was used for propagation and preparation of the 
pEGFP-N1 (Clontech Laboratories) and pcDNA3.1 (Invit-
rogen, Carlsbad, CA) plasmids. pEGFP-N1 encodes a red-
shifted variant of wild-type GFP which has been optimized 
for brighter fl uorescence and higher expression in mamma-
lian cells (Ghaemi et  al. 2010). For constructing pcDNA3.1 
HPV-16 E7 expression vector, the HPV-16 E7 gene was 
digested with EcoRI and XhoI from the pUC18 vector using 
suitable restriction enzymes to be ligated into pcDNA3.1 
backbone, as we described before (Ghaemi et  al. 2010). Th e 
plasmids were extracted according to the manufacturer ’ s 
instructions and dissolved in endotoxin-free Tris-EDTA 
(Sigma, St. Louis, MO). 
 CS depolymerization 
 CS with the deacetylation degree of 95% and the molecular 
weight (MW) of 360 kDa was purchased from the Primex 
(Karmoy, Norway) and depolymerized by a chemical reac-
tion as previously described (Akhlaghi et  al. 2010) to obtain 
the low molecular weights of CS. Briefl y, 10 ml of NaNO2 
solutions (8 mg/ml concentrations in deionized water) was 
added to the CS solution (2 g in 100 ml of acetic acid 6% 
vol/vol) at room temperature under magnetic stirring for 
1 hour. Low molecular weight CS was precipitated by raising 
the pH to 9 by addition of 4 M NaOH drop wise. Th e white-
yellowish solid was fi ltered and washed thrice with acetone 
(Merck) and dissolved in a minimum volume of acetic acid 
0.1 N (Merck). Purifi cation was performed by subsequent 
dialyses (Sigma dialyses tubes MW cutoff  12 kDa) against 
1 L deionized water (twice for 90 minutes and once over-
night). Th e low molecular weight CS was freeze-dried and 
then stored at 4 ° C. 
 Molecular weight measurement 
 Th e molecular weight of depolymerized CS was determined 
by gel permeation chromatography (GPC) using pullulane 
standards (Atyabi et  al. 2008). All chromatograms were 
generated on an Agilent 1100 Liquid Chromatographer 
(Agilent Technologies) and the eluting fraction was followed 
up by a refractive index signal detector. Th e mobile phase 
comprised of 0.2 M acetic acid and 0.1 M sodium acetate 
(both from Merck) at a fl ow rate of 4 ml/min. Th e chro-
matographic procedures were performed at 23 ° C. Th irty 
milligrams of depolymerized CS was dissolved in 10 ml of 
0.2 M acetic acid and 0.1 M sodium acetate. Th e mixture 
was analyzed by the GPC system using the narrow method. 
 CS NP preparation 
 CS NPs were prepared according to the ionotropic gela-
tion technique with TPP cross-linker (Merck, Darmstadt, 
Germany) as described previously (Yousefpour et  al. 2011). 
CS and TPP were separately dissolved in ultrapure water in 
order to obtain CS/TPP ratios 3/1. CS NPs were immediately 
produced by adding a fi xed volume of TPP (1 ml) solution 
drop wise to a fi xed volume of CS solution (3ml) under 
1000 rpm magnetic stirring at room temperature. 
 Size and zeta potential determination 
 Th e hydrodynamic mean diameter of prepared CS NPs was 
determined by dynamic light scattering using Nano-Zetasizer 
(Malvern Instruments, Worcestershire, United Kingdom) 
with a wavelength of 633 nm at 25 ° C with an angle detection 
of 90 ° . Th e samples were diluted with freshly fi ltered deion-
ized water and all measurement was done thrice. 
 Th e zeta potential of prepared CS NPs was determined 
using laser Doppler electrophoresis using Zetasizer (Nano-ZS 
Malvern Instruments). All samples were diluted (1:5) in 
deionized water and each sample was measured thrice. 
 Scanning electron microscopy 
 Th e surface morphology of prepared CS NPs was observed 
using scanning electron microscopy (SEM) (XL 30; Philips, 
Eindhoven, the Netherlands). Th e NP suspensions were sta-
bilized on an aluminum disk (Marubeni, America) and dried 
at room temperature. Th e dried NPs were covered with a thin 
layer of gold metal using a sputter coater (SCD 005; Bal-Tec, 
Balzers, Switzerland). 
 Complex formation between CS NPs and pDNA 
 CS/pDNA complexes were developed at N/P ratios of 
0.1, 0.5, 1, 2, 4, 8, and 16 by adding the pDNA solution to the 
 Figure 1. Chemical structure of chitosan. 
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prepared CS NP ’ s solution. Th e solution was slowly pipetted 
and vortexed for 3 – 5 s to commence complex formation 
and was left for 1 h at room temperature to entirely establish 
the CS/DNA complexes. 
 Th e binding of pDNA with CS NPs was confi rmed by 
electrophoresis. Samples with diff erent N/P ratios, ranging 
from 0.1 to 16, were electrophoresed on to 0.8% agarose gel 
in Tris – acetate/EDTA (TBE) buff er at 40 V for 60 min. Th en, 
gels were stained with ethidium bromide and visualized 
with a UV transilluminator (Cleaver, Germany). 
 DNA release from CS NPs 
 In vitro release of DNA from CS NPs was studied by cen-
trifugation at 4 ° C, 14,000 g for 30 min, after which the com-
plex was resuspended in 800 ml phosphate-buff ered saline 
(PBS, pH 7.4) and incubated at 37 ° C under 100 rpm stirring. 
At each marked time point, the mixture was centrifuged at 
14,000 g for 30 min and DNA content in the supernatant 
was measured spectrophotometrically at 260 nm (Yuan 
et  al. 2009). 
 In vitro transfection study 
 Th e  in vitro transient transfection studies were performed 
in Chinese hamster ovary (CHO) (Pasteur Institute of 
Iran) cell line. Th e CHO cell line was passaged two days 
before the experiment to promote good proliferation and 
cell physiology. Low passage CHO cells (not more than 30 
passages) were cultivated 24 h into 24-well plates at a 
density of 5    10 4 cells/cm 2 in 1ml of growth medium 
(RPMI-1640 containing 10% FBS, complemented with 
2 mM L-glutamine, 100 U/ml penicillin and 100  μ g/ml 
streptomycin). Before transfection, the medium was 
removed and the cells were washed with phosphate-
buff ered saline (PBS, pH 7.4), and then replaced with 
150  μ l of fresh culture medium without FBS. Th e cells were 
incubated with 100  μ l of the CS/pDNA complexes contain-
ing 5  μ g of pDNA and maintained 24 h at 37 ° C under 5% 
CO 2 (Weecharangsan et  al. 2008). Cells transfected with 
lipofectamine and naked plasmid were used as controls. 
After transfection, the medium was replaced by 1 ml of 
fresh growth medium, and the cells were maintained for 
24 h at 37 ° C under 5% CO 2 . All transfection studies were 
performed in triplicate and GFP expression in transfected 
cells was analyzed using fl uorescence microscopy. 
 Cytotoxicity studies 
 Cytotoxicity evaluation was performed with MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) 
analysis. CHO cells were cultivated on 96-well plates at a 
density of 5    10 4 cells/well in 150  μ l fresh culture medium 
supplemented with 10% FBS. Prior to transfection, the 
medium was removed and the cells were washed with 
PBS, and then supplied with 15  μ l of fresh culture medium 
without FBS. CS and CS – pDNA suspensions (100  μ l) were 
then added at various concentrations (N/P ratios of 0.1 
to 16), respectively. After 6 h of incubation, the medium 
was changed with 150  μ l fresh culture medium containing 
10% FBS. Cell viability was determined using MTT after 
72 h incubation by measuring absorbance at 570 nm. Th e 
viability of nontreated control cells was arbitrarily deter-
mined as 100%. 
 SDS-PAGE and western blotting 
 The expression of HPV-16 E7 proteins from CS – pDNA 
complexes in CHO cells was performed by SDS-PAGE and 
western blot analysis (Ghaemi et  al. 2011). In SDS-PAGE 
analysis, the extracted total proteins lysed in SDS-PAGE 
sample loading buffer, and lysates separated by SDS-
PAGE, and staining by coomassie blue R250. For blotting 
separated proteins by SDS-PAGE, transferred onto poly-
vinylidene difluoride membranes (Roche, Germany), and 
hybridized with the monoclonal HPV-16 E7 mouse anti-
body (Abcam, UK), and detection performed with goat 
anti-mouse secondary antibody conjugated to alkaline 
phosphate as in secondary antibody solution. Color 
was developed by incubating the membrane in Di Amino 
Banzedin (DAB). 
 Statistical analysis 
 Statistical analysis of cell viability and  in vitro release of the 
plasmids were performed using Student ’ s t-test. A value of 
 P less than 0.05 was considered to be signifi cant. 
 Results 
 Preparation and characterization of NPs 
 To obtain the desired size range for NPs, low molecular 
weight CS polymers were necessary; hence, an oxidative 
depolymerization method was applied. Molecular weight 
 Figure 2.  (a) Zeta potential of prepared nanoparticles and (b) size distribution of prepared nanoparticles both obtained from nanosizer. 
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fi gure, the NPs could keep most of their content in the dis-
solution medium in early stage of insertion in the medium 
which simulates condition of the  in vivo . About 90% of the 
content was released in 70 h. 
 In vitro transfection study of CS NPs 
 Th e  in vitro transfection study was performed using CHO 
cell line and EGFP-N1 as marker gene. EGFP expression 
in cells investigated through fl uorescence microscopy. 
EGFP expression was observed in CHO cells transfected with 
CS – pEGFP NPs in a similar extent to the control cells which 
were transfected with lipofectamine. Th is indicates that CS 
NPs can be transfected and express green fl uorescent pro-
tein in mammalian cells. Th e results are shown in Figure 6. 
 Cytotoxicity of CS NPs on CHO cells 
 Cytotoxicity evaluation was studied to determine the safety 
of prepared NPs as a carrier for DNA. Th e percentage of 
viable cells was determined using an MTT reduction assay. 
In this experiment, the viability of nontreated control cells 
was considered as 100% and the viability of the NPs prepared 
through CS/pDNA complex at various N/P ratios (0.1 to 16) 
was measured in CHO cells and expressed as percentage of 
the viable cells to control. 
 As shown in Figure 7, 72-h prolonged stimulation 
with 0.1 to 16 N/P ratio caused a decrease in the viability 
of the cells. On the other hand CHO cells in a non-dose-
dependent manner caused slightly decrease in cell viability. 
Around 28% of CHO cells suff ered cell death at treatment 
of N/P ratio of 8 and 20% of them died at N/P ratio of 0.5 in 
comparison with untreated cell. However cells treated with 
naked pDNA had suff ered from death up to 15%. Regarding 
these observations (comparison between results obtained 
from naked pDNA and NPs containing pDAN), cells treated 
with NPs have reserve about 85% of their viability in com-
parison with cells being in contact to naked pDNA, one can 
conclude acceptable safety for prepared NPs. 
 SDS-PAGE and western blot 
 To evaluate the expression of HPV-16 E7 gene in the 
CHO cells, western blot analysis using monoclonal mouse 
anti-HPV E7 antibody was used. 
of depolymerized CS (12 kDa) was determined using GPC 
using pullulan standards. 
 Mean hydrodynamic diameter and zeta potential of pre-
pared NPs are shown in Figure 2. NPs had sizes ranging from 
40 to 150 nm. A narrow size distribution (PDI: 0.149) could 
be seen with a mean diameter of about 70 nm. Th e mean 
zeta potential of NPs was approximately    20 mV. 
 Figure 3 shows a SEM image of the CS NPs containing 
gene. Analysis of the images shows prepared NPs had spher-
ical-shaped structures with smooth surfaces (Figure 3). 
 Gel retarding analysis 
 Th e complex formation between CS NPs and pDNA at dif-
ferent N/P ratios (0.1 to 16) was analyzed by 0.8% agarose 
gel electrophoresis in TBE buff er along with naked pDNA as 
control. Sample was analyzed using electrophoresis at 40 V 
for 60 min. Figure 4 showed the naked pDNA could migrate 
in gel, while the pDNA loaded in CS NPs was immobile and 
remained in the loading wells when N/P ratio was above 1, 
which illustrated the complete complexation of pDNA with 
CS in the NPs (Figure 4). 
 In vitro release study 
 To evaluate the stability of CS/pDNA, the release behavior 
of pDNA from NPs in 100 h time duration at diff erent time 
points was studied and measured via UV spectrophotom-
etry. Th e results are shown in Figure 5. As can be seen in the 
 Figure 3. Scanning electron microscopy of prepared nanoparticles. 
Morphology of nanoparticles is spherical with smooth surface. 
 Figure 4. Agarose gel electrophoresis analysis of CS/pDNA 
complexes to determine complex formation. Sample were analyzed 
in 0.8% agarose gel by electrophoresis at 40 V for 60 min. Lane 
(zur Hausen 1996) pDNA plasmid; lanes (Bosch et  al. 1995, Melief 
et  al. 2000, Duggan et  al. 1998, Chen et  al. 2000, Somia and Verma 
2000, Pouton and Seymour 2001, Ferber 2001) CS/pDNA complexes at 
N/P ratios of 0.1, 0.5, 1, 2, 4, 6, 8 and 16, respectively. 
 Figure 5.  In vitro release of pDNA from chitosan nanoparticles in 
PBS (PH 7.4). At each marked time point, the mixture was centrifuged 
at 14,000 g for 30 min and DNA content in the supernatant was 
measured spectrophotometrically at 260 nm (Mean   S.D,  n    3). 
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 SDS-PAGE and western blot analysis were performed 
on total extracted proteins, 72 h after transfection. Th is 
analysis showed an expression of HPV-16 E7 11 kDa from 
CS NPs (Figure 8). Transfected CHO Cell lysate with naked 
pDNA and lipofectamine was used as control (lane 1 and 2, 
respectively). 
 Discussion 
 In this study, CS NPs were prepared using the ionotropic 
gelation technique with TPP cross-linker and used as an 
effi  cient nonviral gene delivery carrier for HPV-16 E7 gene. 
NPs were prepared using this method which is simple, 
quick, economical, and requires no toxic solvents compared 
to those of the other methods (Hallaj-Nezhadi et  al. 2011). 
In the present study intended to produce NPs of under 
100 nm diameter to facilitate the entrance of the particles to 
the cells. Th e resultant NPs showed mean diameter of about 
70 nm with spherical shape and a narrow size distribution 
(PDI: 0.149). Besides diff erent CS /pDNA (N/P) ratios of the 
preparation designed to fi nd the optimum N/P ratio with 
desired conditions. It was observed that NP size was irrel-
evant to the applied N/P ratios, because NPs were already 
formed when pDNA was added. Similar observations have 
been reported by other studies in which, this method has 
been used for encapsulation of DNA (Hallaj-Nezhadi et  al. 
2011, Nahaei et  al. 2013, Vimal et  al. 2013). Lavertu et  al. 
(2006) also reported that if the CS molecular weight is high 
enough (MW    10kDa), N/P ratio would not have a signifi -
cant eff ect on particle size. Danielsen (2004) suggested that 
if the CS MW is high enough to condensate the DNA, than 
the particle size would mostly depend on the particular 
properties of the DNA molecule. 
 Very high loading effi  ciency yield was further observa-
tion that was found during preparing NPs with this method. 
Th is can be explained by the presence of high positive 
charge on the surface of NPs (   20 mV) (Nahaei et  al. 2013) 
which attracts negatively charged pDNA on the surface. In 
previous studies, it was discovered that addition of tripoly-
phosphate for preparing NPs provides well-condensed and 
very stable NPs (Yousefpour et  al. 2011). Tripolyphosphate 
is negatively charged, therefore it remains into CS polymers 
and this may explain the high loading effi  ciency of prepared 
NPs. If NPs were not stable enough, CS molecules would 
expel from the particles because of the same electric charge 
repulsion, therefore making less condensed and smaller 
NPs which have very low loading effi  ciency (Jayakumar 
et  al. 2010, Mao et  al. 2010). Jayakumar et  al. and Mao et  al. 
studied the inclusion of a negatively charged polymer into 
CS polymers and concluded that the inclusion increases 
stability of CS NPs and therefore increases gene delivery 
ability on CS as a carrier. Our fi ndings were in accordance 
with their studies. To investigate the stability of NPs and 
their ability to successfully integrate with the pDNA, gel 
electrophoresis method was used. In this study, eight dif-
ferent N/P ratios were examined. Accordingly we observed 
that NP stability was highly dependent on the N/P ratio. 
N/P ratios above 1 had the most stabilized NPs, where, in 
NPs with N/P ratios below that, pDNA was easily released 
 Figure 6. EGFP expression in CHO cell lines transfected by (a) Nanoparticles and (b) Lipofectamine. Cells were analyzed 48 h after transfection, 
and green fl uorescence could be seen in cells treated with CS/pEGFP and lipofectamine. 
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 Figure 7. Cell viability assay in CHO cells. Cell viability was determined 
72 h after incubation using MTT. Th e viability of non-treated control 
cells was arbitrarily determined as 100%. Results are expressed as the 
mean   SD ( n    3). 
 Figure 8. Western blot analyses of CHO cells infected with CS/pDNA 
nanoparticles. pcDNA plasmid encoding HPV-16 E7 without Chitosan 
nanoparticles, control (lane 1), pcDNA plasmid encoding HPV-16 E7 
with lipofectamine (lane 2), pcDNA plasmid encoding HPV-16 E7 with 
chitosan nanoparticles (lane 3). 
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 Conclusion 
 Observations in this study revealed that CS/pDNA NPs, 
prepared with ionotropic gelation method with N/P ratio 
of 1 to 16, have provided a promising formulation for pDNA 
delivery. Using CS as a carrier brought an opportunity for 
effi  cient nonviral gene delivery although the effi  ciency of 
CS as a gene carrier is relatively low compared to viral gene 
delivery methods. However more investigation should be 
conducted aiming formulations less toxic with higher gene 
delivery capabilities. 
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from NPs and migrated in the gel, therefore it was deduced 
that although preparing NPs with this method yields high 
loading effi  ciency it does not necessarily mean pDNA will 
remain on the surface of NPs. In another experiment release 
behavior of NPs were assessed. To have effi  cient gene deliv-
ery we have to make sure pDNA release from CS is optimized 
in a way that it does not release in blood circulation before 
reaching target cells and it eventually must be released from 
NPs inside the nucleus. Th erefore, it should be considered 
that we must strike a balance between stability and effi  cient 
binding (Yuan et  al. 2009). In this study in 70 h the cumu-
lative drug release from NPs was approximately 90%. Th is 
simulated the  in vivo condition and revealed that CS NPs 
had potential for carrying and protecting pDNA. 
 Another attempt was made to evaluate their transfection 
effi  ciency in CHO cells. NPs with the desired size diameter 
and the highest loading effi  ciency that had enough stability 
obtained from gel electrophoresis studies were chosen for 
testing transfection effi  ciency in cell culture. Th e human 
cytomegalovirus promoter of the pcDNA3.1 has been shown 
to be very powerful in CHO cells, therefore CHO cell line 
is proved to be highly effi  cient in transfection with genetic 
material, and this was previously investigated and reported 
by our team (Ghaemi et  al. 2011). However, CHO cell line 
cannot be considered an ideal replacement for human cell 
lines in experimental studies since it does not carry all of the 
sugar-transferring enzymes that are present in human cell 
lines (Dutta et  al. 2012). 
 To investigate transfection effi  ciency of NPs pEGFP was 
employed. pEGFP is a plasmid that produces fl uorescent 
protein inside the transfected cells. Th e green fl uorescent 
observed by fl uorescent microscope is an indication of suc-
cessful transfection of pEGFP inside the cells. Other stud-
ies from our team and also other articles showed little or 
no cytotoxic eff ects of CS in cell culture. Nevertheless the 
cytotoxicity of prepared NPs as a carrier using the MTT 
viability assay to investigate whether using CS as a carrier 
for E7 delivery poses any threat to target cells viability. In 
this experiment NPs produced with diff erent N/P ratios was 
utilized. Results revealed no signifi cant correlation between 
N/P ratio and cell viability. Th e viability of cells treated 
with NPs containing pDNA was between 70 to 80% while, 
the viability of untreated cells and cells treated with naked 
pDNA was 100% and 85%, respectively. Th is observation 
shows CS as a carrier has some undesired eff ects on treated 
cells. Th erefore it demands more investigation to prepare 
a formulation to lessen undesired eff ects of CS on target 
cells. Western blot analysis was performed to evaluate the 
expression of HPV-16 E7 gene in CHO cells transfected with 
CS NPs. Th is analysis showed that HPV-16 E7 was success-
fully expressed from CS NPs and could be detected in the 
culture supernatant. Data illustrated in Figure 8 indicate 
that the CS NPs are able to exert expression similar to that of 
lipofectamine, exhibiting high transfection effi  ciency of CS 
NPs. Th is transfection effi  ciency of the vector suggests that 
CS NPs could be a promising nonviral gene delivery vec-
tor, which is easy to synthesize, highly effi  cient and has low 
cytotoxicity. Th e vector could eff ectively deliver exogenous 
HPV-16 E7 in tumor models. 
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